Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Corominas J, Garriga C, Prenafeta A, Moros A, Cañete M, Barreiro A, González-González L, Madrenas L, Güell I, Clotet B, Izquierdo-Useros N, Raïch-Regué D, Gallemí M, Blanco J, Pradenas E, Trinité B, G Prado J, Pérez-Caballero R, Bernad L, Plana M, Esteban I, Aurrecoechea E, Taleb RA, McSkimming P, Soriano A, Nava J, Anagua JO, Ramos R, Martí Lluch R, Corpes Comes A, Otero Romero S, Martínez-Gómez X, Camacho-Arteaga L, Molto J, Benet S, Bailón L, Arribas JR, Borobia AM, Queiruga Parada J, Navarro-Pérez J, Forner Giner MJ, Lucas RO, Vázquez Jiménez MDM, López Fernández MJ, Alvarez-Mon M, Troncoso D, Arana-Arri E, Meijide S, Imaz-Ayo N, García PM, de la Villa S, Rodríguez Fernández S, Prat T, Torroella È, Ferrer L.
Corominas J, et al. Among authors: soriano a.
Vaccine. 2025 Jan 13;47:126685. doi: 10.1016/j.vaccine.2024.126685. Online ahead of print.
Vaccine. 2025.
PMID: 39809095